// App-Quantinova.ai

TPS8614 : The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.

Researchers

Presenter

  • Michaela Liedtke

Principal Investigators

  • Giampaolo Merlini

  • Brendan M. Weiss

  • Jeffrey A. Zonder

  • Jackie Walling

  • Gene Kinney

  • Marty Koller

  • Morie A. Gertz

  • Heather Jolie Landau

  • Ray Comenzo

  • David C. Seldin

Medical Centers

  • Prothena, San Francisco, CA

  • Solomont Center for Hematology and Oncology, Boston, MAMemorial Sloan Kettering Cancer Center, New York, NYTufts University School of Medicine, Boston, MA

  • Karmanos Cancer Institute, Detroit, MI

  • Mayo Clinic, Rochester, MN

  • University of Pavia, Pavia, Italy

  • JW Consulting, Hillsborough, CA

  • Stanford University Cancer Institute, Stanford, CA

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Congestive heart failure

  • AL Amyloidosis

  • Heart muscle disease

  • Amyloid disease

Biomarkers

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • NEOD001

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • NCT02312206

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved